Hansen L Wong[Author] - Search Results

Year	Number of Results
2003	2
2005	2
2008	1
2016	1
2022	1
2024	1

1

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.

Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz MT, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas JM, Gordon PR, Brüggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. Jabbour E, et al. Among authors: wong hl. Am J Hematol. 2024 Apr;99(4):586-595. doi: 10.1002/ajh.27227. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38317420

2

Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.

Katz DA, Morris JD, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, Viardot A, Martín García-Sancho A, Rodríguez-García G, Bastos-Oreiro M, Lee ST, Kormany W, Chen Y, Wong HL, Anderson AA, Katlinskaya Y, Avilion AA, Dai T, González-Barca E. Katz DA, et al. Among authors: wong hl. Leuk Lymphoma. 2022 Sep;63(9):2063-2073. doi: 10.1080/10428194.2022.2064981. Epub 2022 May 3. Leuk Lymphoma. 2022. PMID: 35503708 Free article. Clinical Trial.

3

Mitochondrial protein targets of thiol-reactive electrophiles.

Wong HL, Liebler DC. Wong HL, et al. Chem Res Toxicol. 2008 Apr;21(4):796-804. doi: 10.1021/tx700433m. Epub 2008 Mar 7. Chem Res Toxicol. 2008. PMID: 18324786 Free PMC article.

4

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.

Infante JR, Mendelson DS, Burris HA 3rd, Bendell JC, Tolcher AW, Gordon MS, Gillenwater HH, Arastu-Kapur S, Wong HL, Papadopoulos KP. Infante JR, et al. Among authors: wong hl. Invest New Drugs. 2016 Apr;34(2):216-24. doi: 10.1007/s10637-016-0327-x. Epub 2016 Feb 29. Invest New Drugs. 2016. PMID: 26924128 Clinical Trial.

5

Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine.

Wong HL, Murphy SE, Hecht SS. Wong HL, et al. Chem Res Toxicol. 2005 Jan;18(1):61-9. doi: 10.1021/tx0497696. Chem Res Toxicol. 2005. PMID: 15651850

6

Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes.

Wong HL, Zhang X, Zhang QY, Gu J, Ding X, Hecht SS, Murphy SE. Wong HL, et al. Chem Res Toxicol. 2005 Jun;18(6):913-8. doi: 10.1021/tx0500777. Chem Res Toxicol. 2005. PMID: 15962925

7

Comparative metabolism of N-nitrosopiperidine and N-nitrosopyrrolidine by rat liver and esophageal microsomes and cytochrome P450 2A3.

Wong HL, Murphy SE, Wang M, Hecht SS. Wong HL, et al. Carcinogenesis. 2003 Feb;24(2):291-300. doi: 10.1093/carcin/24.2.291. Carcinogenesis. 2003. PMID: 12584180

8

Preferential metabolic activation of N-nitrosopiperidine as compared to its structural homologue N-nitrosopyrrolidine by rat nasal mucosal microsomes.

Wong HL, Murphy SE, Hecht SS. Wong HL, et al. Chem Res Toxicol. 2003 Oct;16(10):1298-305. doi: 10.1021/tx0340495. Chem Res Toxicol. 2003. PMID: 14565771

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year